MUMBAI, India, Sept. 28 -- Intellectual Property India has published a patent application (202647112796 A) filed by Perseus Proteomics Inc. on September 21, 2026, for Anti-Cdh3 Humanized Antibody And Use Thereof.
Inventors include Akiyoshi Hiroko; Kaneko Sayuri; Ishii Keisuke; and Hagiwara Shinji.
The application for the patent was published on September 25, 2026, under issue no. 39/2026.
Abstract: The present invention addresses the problem of producing a novel anti-CDH3 humanized antibody and providing, by using the antibody, an (anti-CDH3 humanized antibody)-drug conjugate capable of more efficiently killing CDH3-expressing cancer cells. According to the present invention, either of the following antibodies is provided. (1) An anti-CDH3 humanized antibody having a heavy chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 1 and a light chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 2; or (2) an anti-CDH3 humanized antibody having a heavy chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 3 and a light chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 4.
Disclaimer: Curated by HT Syndication.
